Acquisition by Fisher Mary of 5000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3
| DRMAW Stock | USD 0.01 0.00 0.00% |
Slightly above 56% of all Dermata Therapeutics' sophisticated investors are looking to take a long position. The analysis of the overall investor sentiment regarding Dermata Therapeutics Warrant suggests that some traders are interested. Dermata Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Dermata Therapeutics' earnings reports, geopolitical events, and overall market trends.
Dermata |
Filed transaction by Dermata Therapeutics Warrant Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Dermata Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Dermata Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Dermata Therapeutics Fundamental Analysis
We analyze Dermata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Dermata Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Dermata Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dermata Therapeutics stock to make a market-neutral strategy. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics with similar companies.
Peers
Dermata Therapeutics Related Equities
| TFFP | Tff Pharmaceuticals | 9.68 | ||||
| MOLN | Molecular Partners | 0.17 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| INBX | Inhibrx | 2.37 | ||||
| ELVN | Enliven Therapeutics | 4.05 |
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.